Jorge Jorge

Dr. Jorge Jorge


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
JJJorge Jorge
Jorge Jorge
ESEdmundo Santos
Edmundo Santos
IAInês Asseiceira
Inês Asseiceira
SJSylvia Jacob
Sylvia Jacob
CRCarmen Ribes-Koninckx
Carmen Ribes-Koninckx
The worldwide incidence of allergic diseases has been continuously increasing, and up to one in every five people are currently affected by these medical conditions. Although seldom fatal, allergies have a profound impact on children’s growth, development, and quality of life, besides being associated with heavy healthcare costs and resource utilisation. In this context, a group of experts in nutrition, paediatric gastroenterology, allergology, and neonatology joined forces to discuss the role of infant formulas in the primary prevention of allergies in infants for whom breastfeeding is not an option and who are at risk of developing allergies. The topics discussed included the assessment of risk, the impact of the microbiota on the modulation of immune tolerance, and the added value of certain formula characteristics, namely, protein integrity (hydrolysed protein vs. intact protein) and the addition of prebiotics, probiotics, or synbiotics. This article describes the latest evidence on each of the above-mentioned points, as well as a number of recommendations made by the experts to guide counselling of parents in the choice of a formula for infants at risk of allergy. Overall, the experts highlighted family history and dysbiosis-promoting factors (namely, caesarean delivery and antibiotic use) as two of the most important risk factors for allergy development. Moreover, in line with international guidelines, the panel advocated that intact protein formula should be offered to all bottle-fed healthy infants, irrespective of their allergic risk (with the exception of short-term bottle feeding of otherwise breastfed babies in their first week of life, for whom a hydrolysed formula may be advisable). Finally, the experts agreed that the use of prebiotic-, probiotic-, or synbiotic-enriched formulas should be considered in infants at risk of developing allergies.

27 November 2021
Verified
Book Chapter
Closed access
PDF file
IPIsabel Polanco
Isabel Polanco
JJJorge Jorge
Jorge Jorge

1 March 2014 in GE Jornal Português de Gastrenterologia
Verified
Journal Article
Open access
TCTeresa Almeida Campos
Teresa Almeida Campos
SÁSofia Águeda
Sofia Águeda
JRJoana Rebelo
Joana Rebelo
AGAmérico Gonçalves
Américo Gonçalves
RLRosa Lima
Rosa Lima
JJJorge Jorge
Jorge Jorge
ResumoIntroduçãoEm idade pediátrica, o tratamento da doença de Crohn deve não só assegurar o controlo dos sintomas, mas também induzir remissão, permitindo o normal crescimento e desenvolvimento dos doentes. O infliximab tem-se mostrado eficaz no controlo da doença em crianças e adolescentes sem resposta ao tratamento de primeira linha, embora em 30-55% destes ocorra falência, com necessidade de ajuste terapêutico. Estudos pediátricos recentes mostraram eficácia semelhante entre a redução do intervalo de 8 para 6/7 semanas e o aumento da dose para 10mg/kg ou encurtamento do intervalo até 4 semanas.Objetivo e métodosEstudo descritivo, retrospetivo dos doentes pediátricos com diagnóstico de doença de Crohn, que efetuaram tratamento com infliximab nos últimos 5 anos, e avaliação das situações de falência terapêutica.ResultadosForam incluídos 16 doentes (10M, 6F) em que, por não ser conseguida remissão duradoura da doença, foi instituído tratamento com infliximab em esquema de indução, seguido de 5mg/kg cada 8 semanas. Na maioria dos doentes, este tratamento foi iniciado 10 meses após o diagnóstico. Em 8 (50%) verificou-se recaída clínica e/ou analítica, em média após 10 ciclos de tratamento (mediana de 6,5), o que levou a ajuste do esquema terapêutico: 6 (75%) encurtaram o intervalo para 6/7 semanas, um (12,5%) encurtou o intervalo para 4 semanas e um (12,5%) aumentou a dose para 10mg/kg. Dos 6 doentes com dose de 5mg/kg e intervalo de 6/7 semanas, todos tiveram resposta imediata favorável mas 4 necessitaram a longo prazo de aumentar a dose para 10mg/kg, encontrando-se destes 2 em remissão. A remissão da doença com infliximab foi de 81,2%.DiscussãoO tratamento com infliximab mostrou eficácia no controlo da doença de Crohn e redução da necessidade de corticoterapia, mas revelou-se necessário proceder a ajustes de dose, o que frequentemente ocorreu ainda durante o primeiro ano de tratamento. Manipulações no sentido de aumentar a dose ou encurtar o intervalo poderão ser determinadas pela clínica específica de cada doente. A previsível necessidade de ajustar o tratamento ao fim de poucos meses de tratamento justifica que a opção pela terapia biológica na doença de Crohn seja cuidadosamente ponderada, após falência de outras opções iniciais.AbstractIntroductionTreatment of Crohn disease in pediatric patients must ensure not only symptom control but also remission, allowing normal growth and development. Infliximab has been shown to be effective in controlling disease in children and adolescents unresponsive to first-line treatment, although 30 to 55% of failure occurs, requiring therapeutic adjustments. Recent pediatric studies have shown that the efficacy of reducing the range from 8 to 6/7 weeks, increasing the dose to 10mg/kg dose or shortening the interval up to 4 weeks is similar.Objective and methodsRetrospective descriptive study of pediatric patients who were diagnosed with Crohn Disease and had infliximab treatment in last five years, with evaluation of treatment failure situations.ResultsWe included 16 patients (10 males, 6 females) treated with infliximab induction regimen, followed by 5mg/kg every 8 weeks. In most patients, treatment was initiated 10 months after diagnosis. In 50% there was clinical and/or analytical relapse, on average after 10 cycles of treatment (median 6.5), leading to an adjustment of the therapeutic regimen: 6 shortened the interval to 6/7 weeks, 1 shortened the interval to 4 weeks and 1 increased the dose to 10mg/kg. Of the 6 patients with 5mg/kg dose and interval of 6/7 weeks, all had initial favorable response but 4 required an increase of the dose to 10mg/kg, 2 of them are in remission. The disease remission with infliximab was 81.2%.DiscussionTreatment with infliximab was effective in controlling Crohn disease and in reducing the need of steroids, but dose adjustments were necessary, often occurring in the first year of treatment. Clinical changes determined the need of dose or interval increases or reductions. The predictable need to adjust treatment after a few months of treatment justifies that the choice of biologic therapy in Crohn disease has to be carefully considered after failure of other options

11 August 2017 in Current Treatment Options in Allergy
Verified
Journal Article
Closed access
PDF file
MTMarta Tavares
Marta Tavares
JJJorge Jorge
Jorge Jorge